Last updated: September 25, 2026
Revatio is Pfizer’s sildenafil citrate product for pulmonary arterial hypertension (PAH). Its commercial position has shifted from branded specialty therapy to a largely generic market. The active ingredient is no longer protected by the core compound patent, and multiple generic manufacturers supply sildenafil 20 mg tablets and other PAH formulations. Pfizer’s continuing value is concentrated in brand recognition, established PAH prescribing, hospital access, and the residual economics of formulations and distribution rather than exclusivity.
What is Revatio and how is it used?
Revatio contains sildenafil citrate, a phosphodiesterase-5 inhibitor that increases cyclic guanosine monophosphate and relaxes pulmonary vascular smooth muscle. The FDA approved Revatio in 2005 for improving exercise ability in adults with pulmonary arterial hypertension, classified as WHO Group I disease [1].
The principal FDA-approved presentations are:
| Presentation |
Strength or concentration |
Route |
Commercial role |
| Tablets |
20 mg |
Oral |
Core outpatient product |
| Oral suspension |
10 mg/mL after constitution |
Oral |
Pediatric and swallowing-limited patients |
| Injection |
10 mg/12.5 mL |
Intravenous |
Hospital use when oral therapy is temporarily unavailable |
The labeled adult regimen is 20 mg three times daily. The FDA label does not establish additional efficacy from higher doses in adults with PAH [1].
Revatio is distinct from Viagra even though both contain sildenafil. Viagra is approved for erectile dysfunction, while Revatio is approved for PAH. The different indications have produced separate patent, labeling, pricing and distribution histories.
How large is the Revatio market?
The global market for PAH medicines is substantially larger than the market for sildenafil alone. Revatio competes in a treatment category that includes endothelin-receptor antagonists, prostacyclin-pathway agents, soluble guanylate cyclase stimulators and combination regimens.
The addressable patient population is limited by the rarity of PAH, but treatment duration is often long and therapy is specialist-directed. Commercial demand depends on:
- Newly diagnosed PAH patients receiving first-line or combination therapy.
- Patients maintained on PDE-5 inhibitor therapy.
- Hospital conversion between oral and intravenous sildenafil.
- Pediatric and congenital-heart-disease populations.
- Price-driven substitution from branded Revatio to generic sildenafil.
The market has become increasingly price sensitive. Generic sildenafil is generally used when formulary policy, payer authorization and physician preference permit substitution. Branded Revatio retains value in accounts that use closed specialty-pharmacy networks, hospital protocols or manufacturer-specific reimbursement support.
Public Pfizer filings do not consistently disclose Revatio as a standalone revenue line in recent reporting periods. Pfizer generally aggregates smaller products within broader product or therapeutic-area categories, preventing a reliable current annual-sales figure for Revatio alone [2]. This reporting structure indicates that Revatio is no longer a material standalone driver of Pfizer’s consolidated revenue.
What is the financial trajectory of Revatio?
Revatio’s financial trajectory has four stages.
2005 to the early generic period: branded specialty growth
Following FDA approval in 2005, Revatio benefited from the absence of direct generic competition and the limited number of approved PAH therapies. Revenue was supported by specialist prescribing, chronic use and the broader recognition of sildenafil.
The product did not reach Viagra’s commercial scale. PAH is a smaller market than erectile dysfunction, and treatment decisions are more concentrated among pulmonologists, cardiologists and specialty pharmacies.
Patent-transition period: erosion risk
The loss of core sildenafil exclusivity created pressure on branded pricing. Patent litigation and settlements affected the timing of generic availability in the United States. Generic approval did not necessarily translate into immediate, unrestricted market entry because patent claims, settlement terms and commercial launch decisions controlled effective competition.
Post-generic period: volume retention with price compression
After generic sildenafil became available, Revatio’s branded revenue was exposed to:
- Lower net prices.
- Payer-directed substitution.
- Generic contracting by specialty pharmacies.
- Reduced physician sensitivity to brand selection.
- Generic competition in 20 mg tablets.
Brand demand did not disappear immediately because patients may remain on an established product, and some payers require prior authorization before switching. The economic impact is nevertheless more severe for a chronic oral medicine than for a short-course product because each refill creates a substitution opportunity.
Current period: mature and declining brand economics
Revatio is now a mature product. Its revenue profile is best characterized as declining or stabilized at a low level relative to Pfizer’s largest products, with continuing residual sales from brand-loyal patients, institutional contracts, oral suspension, injection and markets where generic penetration is incomplete.
Pfizer’s financial exposure is limited because Revatio is not a major contributor to group revenue. The larger financial effect is on generic manufacturers, which compete for recurring prescription volume in a specialized but established PAH market.
What patents protect Revatio?
The central patent estate includes the sildenafil compound patent and method-of-use protection for pulmonary hypertension.
| Patent |
Subject matter |
Relevance to Revatio |
Expiration or status |
| U.S. Patent No. 5,250,534 |
Sildenafil and related pyrazolopyrimidinone compounds |
Core active-ingredient protection |
Expired in 2012, including applicable pediatric extension period |
| U.S. Patent No. 6,469,012 |
Use of sildenafil for pulmonary hypertension |
Disease-specific method-of-use protection |
Expired after the core compound patent and delayed generic entry for the PAH indication |
| FDA-approved product and labeling claims |
20 mg tablets, injection and oral suspension |
Regulatory differentiation rather than broad exclusivity |
No current broad compound exclusivity |
The relevant legal distinction is important. Expiration of the compound patent removed protection for sildenafil as a chemical entity. The method-of-use patent could still affect labeling and the commercial timing of a generic product intended for PAH.
Patent protection for a method of treatment does not automatically prevent all sildenafil products from entering the market. An applicant can pursue a Section viii label carve-out that omits the patented indication, subject to FDA and patent-law requirements.
When did Revatio lose exclusivity?
Revatio lost meaningful market exclusivity in stages rather than on a single date.
The sildenafil compound patent expired in 2012, after the applicable pediatric extension. PAH-specific patent protection lasted longer and influenced the timing and scope of generic launches. FDA approvals for generic sildenafil products began during the patent-transition period, but approval dates, launch dates and permitted indications were not identical.
The practical exclusivity timeline is:
| Period |
Market position |
| 2005 to 2012 |
Branded Revatio protected by compound and use-related patent rights |
| 2012 onward |
Core sildenafil compound protection expired |
| 2012 to late 2010s |
Method-of-use claims and litigation affected PAH generic entry |
| Late 2010s onward |
Multiple generic sildenafil suppliers and broad price competition |
| Current market |
Generic-dominated, with limited brand residual demand |
What was the Orange Book status of Revatio?
Revatio was listed in the FDA Orange Book as a prescription drug with patent information associated with sildenafil and its PAH use. Orange Book listings are relevant because they identify patents that a generic applicant must address through an ANDA certification or a labeling carve-out [3].
The main regulatory pathways were:
- Paragraph IV certification, asserting that a listed patent was invalid, unenforceable or would not be infringed.
- Paragraph III certification, deferring approval until patent expiration.
- Section viii statement, omitting a patented method of use from the proposed labeling.
- ANDA approval for bioequivalent sildenafil products.
The Orange Book does not itself establish the date of commercial generic launch. It identifies listed patents and regulatory certification obligations. Patent litigation, settlement agreements and business decisions determine whether an approved ANDA reaches the market.
Which companies challenged Revatio patents?
Generic sildenafil development involved major generic companies, including Teva, Mylan, Dr. Reddy’s Laboratories, Torrent, Aurobindo, Amneal and other ANDA sponsors over time. The exact competitive set varies by dosage form, supplier status and market period.
Generic manufacturers typically challenged or navigated Revatio protection through:
- Paragraph IV certifications against listed patents.
- Section viii carve-outs for PAH-related labeling.
- Settlement agreements that set an agreed launch date.
- Licensing or authorized-generic arrangements.
- Post-expiration ANDA commercialization.
The commercially important issue was not only whether a patent could be invalidated. It was whether the generic could sell sildenafil for the same PAH use without exposing itself to infringement damages or an injunction.
What generic entry risks exist for Revatio?
Generic entry risk is high for the tablet presentation and moderate for more specialized presentations.
Tablets
The 20 mg tablet is the most exposed presentation because:
- The active ingredient is well established.
- Manufacturing is relatively straightforward.
- Bioequivalence is achievable through conventional ANDA development.
- Multiple manufacturers can supply the product.
- Payers have strong incentives to substitute.
Oral suspension
The oral suspension has greater formulation and handling requirements. Generic competition remains possible, but the market is smaller and development economics are less attractive than for tablets.
Injection
The injection is more dependent on sterile manufacturing, hospital contracting, inventory management and institutional demand. These requirements create higher barriers than for tablets, but they do not recreate patent exclusivity.
What formulations are protected by Revatio patents?
Revatio’s strongest historical protection was tied to sildenafil and its therapeutic use, not to a durable formulation platform. The commercial formulations are:
- Immediate-release 20 mg tablets.
- Powder for oral suspension.
- Sterile intravenous solution.
The tablet is the primary generic target. The oral suspension and injection can have practical manufacturing barriers, including stability, dose uniformity, sterile production and hospital procurement requirements. Those barriers are commercial and technical rather than equivalent to a broad, enforceable patent moat.
Is there biosimilar risk for Revatio?
There is no biosimilar risk because Revatio is a chemically synthesized small-molecule drug. Biosimilar pathways apply to biologic products, not sildenafil tablets, oral suspension or injection.
The relevant competitor class is generic sildenafil. FDA approval proceeds through the ANDA pathway based on pharmaceutical equivalence and bioequivalence, not the abbreviated biologics pathway [4].
How does Revatio compare with competing PAH drugs?
Revatio competes with products that differ substantially in mechanism, dosing, route and price.
| Product or class |
Active ingredient |
Mechanism |
Competitive impact |
| Revatio and generic sildenafil |
Sildenafil |
PDE-5 inhibition |
Low-cost oral option |
| Adcirca and generic tadalafil |
Tadalafil |
PDE-5 inhibition |
Longer duration and once-daily dosing |
| Cialis-related tadalafil products |
Tadalafil |
PDE-5 inhibition |
Different primary indication, overlapping molecule class |
| Tracleer and generic bosentan |
Bosentan |
Endothelin-receptor antagonism |
Older oral alternative |
| Letairis and generic ambrisentan |
Ambrisentan |
Endothelin-receptor antagonism |
Combination-therapy competitor |
| Opsumit |
Macitentan |
Endothelin-receptor antagonism |
Branded PAH therapy |
| Adempas |
Riociguat |
Soluble guanylate cyclase stimulation |
Alternative mechanism |
| Remodulin, Tyvaso and epoprostenol products |
Prostacyclin pathway agents |
Vasodilation and antiproliferative effects |
More severe-disease and escalation use |
Generic tadalafil increases pressure on sildenafil, particularly when once-daily dosing improves adherence. Combination treatment also limits direct product substitution because clinicians may use a PDE-5 inhibitor with an endothelin-receptor antagonist rather than choose one product exclusively.
What licensing deals affect Revatio?
No major third-party licensing transaction is a central current driver of Revatio economics. Pfizer developed sildenafil internally and commercialized Revatio through its own global pharmaceutical organization.
The more important arrangements have been generic settlements, supply agreements, authorized-generic structures and payer contracts. These agreements can affect launch timing and net pricing without changing the underlying patent estate.
What patent litigation and settlements affected Revatio?
Revatio’s key litigation risk centered on generic challenges to sildenafil patents and the PAH method-of-use claims. The business consequences included:
- Delayed or restricted generic commercialization.
- Negotiated entry dates.
- Potential use of indication carve-outs.
- Exposure to patent damages if launch occurred at risk.
- Reduced value of the remaining patent term after compound expiry.
The litigation landscape became less consequential after expiration of the principal patent rights. Current disputes, if any, are more likely to concern ANDA infringement, manufacturing patents, labeling, supply agreements or pricing conduct than the basic sildenafil composition.
What is the FDA regulatory status of Revatio?
Revatio remains an FDA-approved prescription treatment for adult PAH. The FDA label includes tablets, oral suspension and intravenous administration [1].
The product’s regulatory position is stable, but its commercial differentiation is limited. FDA approval supports brand continuity and physician familiarity. It does not prevent approval of therapeutically equivalent generic sildenafil products.
The principal regulatory risks are:
- Manufacturing or supply interruptions.
- Labeling changes.
- Safety communications affecting sildenafil use.
- Product-specific quality issues.
- Competition from approved generics.
- Reimbursement restrictions and specialty-pharmacy controls.
What is the geographic coverage of Revatio?
Revatio and sildenafil PAH products are marketed in major pharmaceutical markets, but brand and generic availability differs by jurisdiction. Patent expiration, national regulatory approval, reimbursement policy and local pricing rules determine effective competition.
The United States has the most developed ANDA-driven generic framework. Europe and other markets may use national or centralized procedures, with different launch dates and reference-product rules. In lower-income markets, sildenafil may be supplied under generic names without strong Revatio brand presence.
Geographic revenue erosion therefore occurs unevenly. Pfizer may retain brand sales in markets where substitution is limited, while generic penetration is stronger where reimbursement systems mandate lowest-cost alternatives.
How strong is the Revatio patent estate?
The current patent estate is weak as a barrier to generic competition.
| Factor |
Assessment |
| Core compound patent |
Expired |
| PAH method-of-use protection |
Expired or no longer commercially decisive |
| Tablet formulation protection |
Limited practical strength |
| Injection manufacturing barriers |
Moderate operational barrier, not broad exclusivity |
| Oral suspension differentiation |
Moderate niche protection, limited market size |
| Generic manufacturing capability |
High |
| Payer substitution pressure |
High |
| Brand switching risk |
High |
Revatio has a durable clinical franchise but not a durable patent moat. Its remaining commercial value depends on execution, supply reliability, payer access and physician familiarity.
What generic launch scenarios exist for Revatio?
The likely market scenarios are:
Continued generic price compression
This is the base case for 20 mg tablets. More suppliers create contracting pressure and reduce the economic value of branded Revatio.
Limited brand retention
Pfizer may retain a smaller segment of patients who remain on brand therapy because of prescriber preference, reimbursement arrangements or specialty-pharmacy continuity.
Niche defense through formulations
Oral suspension and injection can preserve narrow revenue pools because they require more specialized manufacturing and distribution. These products cannot offset broad tablet erosion.
Supply-driven price volatility
If a major generic manufacturer exits or experiences a manufacturing disruption, prices can rise temporarily. Such events would reflect supply concentration, not renewed patent protection.
Key Takeaways
- Revatio is Pfizer’s sildenafil citrate product for pulmonary arterial hypertension.
- The compound patent expired in 2012, and later PAH-use protection no longer provides a durable commercial barrier.
- Generic sildenafil is the main competitive threat; biosimilar competition does not apply.
- The 20 mg tablet is the most exposed presentation.
- Oral suspension and intravenous injection have higher operational barriers but smaller markets.
- Pfizer does not consistently report standalone Revatio revenue in recent public filings.
- The product’s financial trajectory is mature and generic-pressured, with limited strategic importance to Pfizer’s total revenue.
- Competitive differentiation now depends on payer access, supply reliability, specialist familiarity and formulation availability rather than patent exclusivity.
FAQs
Is Revatio the same drug as Viagra?
Yes. Both contain sildenafil, but Revatio is approved for pulmonary arterial hypertension and Viagra is approved for erectile dysfunction. They have different labels, dosages, commercial channels and historical patent treatment.
Can sildenafil generic tablets replace Revatio?
Generic sildenafil can replace Revatio when the strength, formulation, indication, prescription and payer requirements align. Substitution depends on local law, pharmacy rules and the prescribing physician.
Why is generic Revatio cheaper than branded Revatio?
The active ingredient and core patent rights are no longer exclusive. Multiple ANDA-approved manufacturers can compete, allowing payers and specialty pharmacies to negotiate lower prices.
Does Revatio have pediatric exclusivity today?
No. Any pediatric exclusivity associated with the original sildenafil patent was temporary and has expired. It does not provide current market protection.
What is the main commercial risk to Pfizer from Revatio?
The main risk is continuing branded-to-generic substitution in chronic PAH therapy. The revenue impact is limited at the Pfizer group level because Revatio is not a major separately reported product.
References
- U.S. Food and Drug Administration. (2023). Revatio (sildenafil citrate) prescribing information.
- Pfizer Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Generic drug facts and ANDA regulatory information.
